

Karl-Erik Andersson

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/7007079/publications.pdf](https://exaly.com/author-pdf/7007079/publications.pdf)

Version: 2024-02-01

135
papers

4,304
citations

137592

32
h-index

119370

62
g-index

138
all docs

138
docs citations

138
times ranked

3804
citing authors

#	ARTICLE	IF	CITATIONS
1	Urinary Bladder Contraction and Relaxation: Physiology and Pathophysiology. <i>Physiological Reviews</i> , 2004, 84, 935-986.	29.1	766
2	Atropine Resistance of Transmurally Stimulated Isolated Human Bladder Muscle. <i>Journal of Urology</i> , 1982, 128, 1368-1371.	0.4	256
3	Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: Pathophysiology and mechanism(s) of action. <i>Neurourology and Urodynamics</i> , 2011, 30, 292-301.	1.5	185
4	Rodent models for urodynamic investigation. <i>Neurourology and Urodynamics</i> , 2011, 30, 636-646.	1.5	166
5	Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence. <i>Current Opinion in Urology</i> , 2009, 19, 380-394.	1.8	161
6	Antimuscarinic Mechanisms and the Overactive Detrusor: An Update. <i>European Urology</i> , 2011, 59, 377-386.	1.9	138
7	Determinates of muscle precursor cell therapy efficacy in a nonhuman primate model of intrinsic urinary sphincter deficiency. <i>Stem Cell Research and Therapy</i> , 2017, 8, 1.	5.6	138
8	Pharmacology of α_1 -adrenoceptor antagonists in the lower urinary tract and central nervous system. <i>Nature Reviews Urology</i> , 2007, 4, 368-378.	1.4	123
9	Lamina propria: The functional center of the bladder?. <i>Neurourology and Urodynamics</i> , 2014, 33, 9-16.	1.5	123
10	The role of the transient receptor potential (TRP) superfamily of cation-selective channels in the management of the overactive bladder. <i>BJU International</i> , 2010, 106, 1114-1127.	2.5	95
11	Detrusor myocyte activity and afferent signaling. <i>Neurourology and Urodynamics</i> , 2010, 29, 97-106.	1.5	89
12	Direct Effects of Adenosine and Adenine Nucleotides on Isolated Human Urinary Bladder and their Influence on Electrically Induced Contractions. <i>Journal of Urology</i> , 1983, 130, 392-398.	0.4	74
13	Phosphodiesterases (PDEs) and PDE inhibitors for treatment of LUTS. <i>Neurourology and Urodynamics</i> , 2007, 26, 928-933.	1.5	71
14	Can incontinence be cured? A systematic review of cure rates. <i>BMC Medicine</i> , 2017, 15, 63.	5.6	68
15	Erectile Dysfunction and Lower Urinary Tract Symptoms. <i>European Urology Focus</i> , 2017, 3, 352-363.	3.1	68
16	Selective β_3 -Adrenoceptor Agonists for the Treatment of Overactive Bladder. <i>Journal of Urology</i> , 2013, 190, 1173-1180.	0.4	63
17	α_1 -Adrenergic receptor subtype expression in myocyte and non-myocyte cells in human female bladder. <i>Cell and Tissue Research</i> , 2010, 342, 295-306.	3.0	62
18	Progressive Vascular Damage May Lead to Bladder Underactivity in Rats. <i>Journal of Urology</i> , 2014, 191, 1462-1469.	0.4	61

#	ARTICLE	IF	CITATIONS
19	Potential Future Pharmacological Treatment of Bladder Dysfunction. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2016, 119, 75-85.	2.5	61
20	Cardiac effects of muscarinic receptor antagonists used for voiding dysfunction. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 186-196.	2.5	56
21	Animal Modelling of Interstitial Cystitis/Bladder Pain Syndrome. <i>International Neurourology Journal</i> , 2018, 22, S3-9.	1.3	56
22	Inhibitory Effects of Nitrendipine on Myometrial and Vascular Smooth Muscle in Human Pregnant Uterus and Placenta. <i>Acta Pharmacologica Et Toxicologica</i> , 1986, 59, 1-10.	0.0	51
23	Correlation of Gene Expression with Bladder Capacity in Interstitial Cystitis/Bladder Pain Syndrome. <i>Journal of Urology</i> , 2014, 192, 1123-1129.	0.4	46
24	New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA. <i>Therapeutics and Clinical Risk Management</i> , 2013, 9, 161.	2.0	44
25	On the Site and Mechanism of Action of β_3 -Adrenoceptor Agonists in the Bladder. <i>International Neurourology Journal</i> , 2017, 21, 6-11.	1.3	43
26	The novel β_3 -adrenoceptor agonist mirabegron reduces carbachol-induced contractile activity in detrusor tissue from patients with bladder outflow obstruction with or without detrusor overactivity. <i>European Journal of Pharmacology</i> , 2013, 699, 101-105.	3.6	41
27	Tramadol Abuse and Sexual Function. <i>Sexual Medicine Reviews</i> , 2016, 4, 235-246.	2.9	39
28	Bladder Capacity is a Biomarker for a Bladder Centric versus Systemic Manifestation in Interstitial Cystitis/Bladder Pain Syndrome. <i>Journal of Urology</i> , 2017, 198, 369-375.	0.4	39
29	Calcium signalling in Cajal-like interstitial cells of the lower urinary tract. <i>Nature Reviews Urology</i> , 2014, 11, 555-564.	3.8	38
30	Prospective pharmacologic therapies for the overactive bladder. <i>Therapeutic Advances in Urology</i> , 2009, 1, 71-83.	2.0	37
31	Fibrosis and the bladder, implications for function ICIERS 2017. <i>Neurourology and Urodynamics</i> , 2018, 37, S7-S12.	1.5	36
32	Oxidative stress and its possible relation to lower urinary tract functional pathology. <i>BJU International</i> , 2018, 121, 527-533.	2.5	33
33	The many faces of impaired bladder emptying. <i>Current Opinion in Urology</i> , 2014, 24, 363-369.	1.8	32
34	Chronic Pelvic Ischemia: Contribution to the Pathogenesis of Lower Urinary Tract Symptoms (<sc>LUTS</sc>): A New Target for Pharmacological Treatment?. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2015, 7, 1-8.	1.3	32
35	Common theme for drugs effective in overactive bladder treatment: Inhibition of afferent signaling from the bladder. <i>International Journal of Urology</i> , 2013, 20, 21-27.	1.1	30
36	Multichannel intrauterine pressure recording by means of microtransducers. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 1979, 58, 115-120.	2.8	29

#	ARTICLE	IF	CITATIONS
37	Treating patients with overactive bladder syndrome with antimuscarinics: heart rate considerations. <i>BJU International</i> , 2007, 100, 1007-1014.	2.5	27
38	Regenerative Medicine Therapies for Stress Urinary Incontinence. <i>Journal of Urology</i> , 2016, 196, 1619-1626.	0.4	27
39	Pharmacotherapy of the overactive bladder. <i>Discovery Medicine</i> , 2009, 8, 118-24.	0.5	26
40	Inhibition of smooth muscle force generation by focal adhesion kinase inhibitors in the hyperplastic human prostate. <i>American Journal of Physiology - Renal Physiology</i> , 2014, 307, F823-F832.	2.7	25
41	TRP Channels as Lower Urinary Tract Sensory Targets. <i>Medical Sciences (Basel, Switzerland)</i> , 2019, 7, 67.	2.9	25
42	Evaluating the safety and potential activity of URO-02 (hMaxi-K) gene transfer by intravesical instillation or direct injection into the bladder wall in female participants with idiopathic (non-neurogenic) overactive bladder syndrome and detrusor overactivity from two double-blind, imbalanced, placebo-controlled randomized phase 1 trials. <i>Neurourology and Urodynamics</i> , 2020, 39, 744-753.	1.5	25
43	Bladder Underactivity. <i>European Urology</i> , 2014, 65, 399-401.	1.9	22
44	Neuroepithelial control of mucosal inflammation in acute cystitis. <i>Scientific Reports</i> , 2018, 8, 11015.	3.4	22
45	Best practices for cystometric evaluation of lower urinary tract function in muriform rodents. <i>Neurourology and Urodynamics</i> , 2020, 39, 1868-1884.	1.5	22
46	Urothelial effects of oral agents for overactive bladder. <i>Current Urology Reports</i> , 2008, 9, 459-464.	2.3	21
47	Fundamentals and clinical perspective of urethral sphincter instability as a contributing factor in patients with lower urinary tract dysfunction. <i>ICIRS 2014. Neurourology and Urodynamics</i> , 2016, 35, 318-323.	1.5	21
48	Current Pharmacologic Approaches in Painful Bladder Research: An Update. <i>International Neurourology Journal</i> , 2017, 21, 235-242.	1.3	21
49	Agents in early development for treatment of bladder dysfunction – promise of drugs acting at TRP channels?. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 749-755.	4.1	21
50	Are oxidative stress and ischemia significant causes of bladder damage leading to lower urinary tract dysfunction? Report from the ICIRS 2019. <i>Neurourology and Urodynamics</i> , 2020, 39, S16-S22.	1.5	21
51	Effects of Allogeneic Bone Marrow Derived Mesenchymal Stromal Cell Therapy on Voiding Function in a Rat Model of Parkinson Disease. <i>Journal of Urology</i> , 2014, 191, 850-859.	0.4	20
52	Translational Research and Functional Changes in Voiding Function in Older Adults. <i>Clinics in Geriatric Medicine</i> , 2015, 31, 535-548.	2.5	19
53	Cell versus Chemokine Therapy in a Nonhuman Primate Model of Chronic Intrinsic Urinary Sphincter Deficiency. <i>Journal of Urology</i> , 2016, 196, 1809-1815.	0.4	19
54	Systematic Review of Combination Drug Therapy for Non-neurogenic Lower Urinary Tract Symptoms. <i>European Urology</i> , 2019, 75, 129-168.	1.9	19

#	ARTICLE	IF	CITATIONS
55	Association of lower urinary tract syndrome with peripheral arterial occlusive disease. PLoS ONE, 2017, 12, e0170288.	2.5	19
56	REGENERATIVE PHARMACOLOGY: THE FUTURE IS NOW. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2007, 7, 79-86.	3.4	18
57	Toll-like receptor 7 is overexpressed in the bladder of Hunner-type interstitial cystitis, and its activation in the mouse bladder can induce cystitis and bladder pain. Pain, 2017, 158, 1538-1545.	4.3	17
58	Characteristics of the mechanosensitive bladder afferent activities in relation with microcontractions in male rats with bladder outlet obstruction. Scientific Reports, 2017, 7, 7646.	3.4	17
59	Therapeutic targets for premature ejaculation. Maturitas, 2011, 70, 26-33.	2.4	16
60	Treatment of lower urinary tract symptoms: Agents for intraprostatic injection. Scandinavian Journal of Urology, 2013, 47, 83-90.	1.0	15
61	Which molecular targets do we need to focus on to improve lower urinary tract dysfunction? ICI&E S 2017. Neurourology and Urodynamics, 2018, 37, S117-S126.	1.5	15
62	Differentiated adipose-derived stem cells for bladder bioengineering. Scandinavian Journal of Urology, 2015, 49, 407-414.	1.0	14
63	Local versus intravenous injections of skeletal muscle precursor cells in nonhuman primates with acute or chronic intrinsic urinary sphincter deficiency. Stem Cell Research and Therapy, 2016, 7, 147.	5.6	14
64	Treatment of Stress Urinary Incontinence with Muscle Stem Cells and Stem Cell Components: Chances, Challenges and Future Prospects. International Journal of Molecular Sciences, 2021, 22, 3981.	4.1	14
65	Preventive Effects of Long-Term Caloric Restriction on Aging Related In Vivo Bladder Dysfunction and Molecular Biological Changes in the Bladder and Dorsal Root Ganglia in Rats. Journal of Urology, 2016, 196, 1575-1583.	0.4	13
66	Extended periprostatic nerve distributions on the prostate surface confirmed using diffusion tensor imaging. BJU International, 2019, 123, 995-1004.	2.5	13
67	Î²3-Receptor Agonists for Overactive Bladder&E S New Frontier or More of the Same?. Current Urology Reports, 2013, 14, 435-441.	2.3	11
68	On the mode of action of mirabegron. Nature Reviews Urology, 2016, 13, 131-132.	3.8	11
69	Nonhuman primate model of persistent erectile and urinary dysfunction following radical prostatectomy: Feasibility of minimally invasive therapy. Neurourology and Urodynamics, 2018, 37, 2141-2150.	1.5	11
70	The serotonin (5&E S hydroxytryptamine) 5&E S HT</sc>₇ receptor is up&E S regulated in Onuf's nucleus in rats with chronic spinal cord injury. BJU International, 2019, 123, 718-725.	2.5	11
71	Gene Therapy for Overactive Bladder: A Review of BK-Channel Î±-Subunit Gene Transfer. Therapeutics and Clinical Risk Management, 2021, Volume 17, 589-599.	2.0	11
72	Age-Related Alterations in Regeneration of the Urinary Bladder after Subtotal Cystectomy. American Journal of Pathology, 2013, 183, 1585-1595.	3.9	10

#	ARTICLE	IF	CITATIONS
73	Serotonin (5-HT) _{2A/2C} receptor agonist (2,5-dimethoxy-4-(diphenyl)-2-aminopropane hydrochloride (DOI)) improves voiding efficiency in the diabetic rat. BJU International, 2015, 116, 147-155.	2.3	10
74	Superoxide overproduction and kidney fibrosis: a new animal model. Einstein (Sao Paulo, Brazil), 2015, 13, 79-88.	0.7	10
75	Intraprostatic injections for lower urinary tract symptoms treatment. Current Opinion in Urology, 2015, 25, 12-18.	1.8	10
76	Efficacy and Initial Safety Profile of CXCL12 Treatment in a Rodent Model of Urinary Sphincter Deficiency. Stem Cells Translational Medicine, 2017, 6, 1740-1746.	3.4	10
77	Intraprostatic injections for lower urinary tract symptoms/benign prostatic enlargement treatment. Minerva Urologica e Nefrologica = the Italian Journal of Urology and Nephrology, 2018, 70, 570-578.	3.9	10
78	Regenerative pharmacology: recent developments and future perspectives. Regenerative Medicine, 2016, 11, 859-870.	1.7	9
79	The efficacy of mirabegron in the treatment of urgency and the potential utility of combination therapy. Therapeutic Advances in Urology, 2018, 10, 243-256.	2.0	9
80	Drugs and future candidates. Canadian Urological Association Journal, 2011, 5, S131-s133.	0.6	9
81	The use of pharmacotherapy for male patients with urgency and stress incontinence. Current Opinion in Urology, 2014, 24, 571-577.	1.8	8
82	Drug therapy of overactive bladder - What is coming next?. Korean Journal of Urology, 2015, 56, 673.	1.2	7
83	Potential of stem cell treatment in detrusor dysfunction. Advanced Drug Delivery Reviews, 2015, 82-83, 117-122.	13.9	7
84	Drugs for the overactive bladder: are there differences in persistence and compliance?. Translational Andrology and Urology, 2017, 6, 597-601.	1.4	7
85	Current concepts of the acontractile bladder. BJU International, 2018, 122, 195-202.	2.5	7
86	Chronic spinal cord injury causes upregulation of serotonin (5-HT) _{2A} and 5-HT _{2C} receptors in lumbosacral cord motoneurons. BJU International, 2018, 121, 145-154.	2.5	7
87	Pharmacokinetic and Pharmacodynamic Properties of a Micro-Dose Nasal Spray Formulation of Desmopressin (AV002) in Healthy Water-Loaded Subjects. Pharmaceutical Research, 2019, 36, 92.	3.5	7
88	Uterine Activity in Diabetes Insipidus. Acta Obstetrica Et Gynecologica Scandinavica, 1977, 56, 381-385.	2.8	6
89	Melatonin Improves Erectile Function in Rats with Chronic Lower Body Ischemia. Journal of Sexual Medicine, 2016, 13, 179-186.	0.6	6
90	Evaluating the Procedure for Performing Awake Cystometry in a Mouse Model. Journal of Visualized Experiments, 2017, , .	0.3	6

#	ARTICLE	IF	CITATIONS
91	Oxidative stress and lower urinary tract symptoms: cause or consequence?. BJU International, 2019, 123, 749-750.	2.5	6
92	Streptozotocin-induced diabetes causes upregulation of serotonin (5-HT)2A/C receptors in lumbosacral cord motoneurons and down regulation of serotonergic paraneurons in the urethra. Brain Research, 2019, 1715, 21-26.	2.2	6
93	Increased autophagy contributes to impaired smooth muscle function in neurogenic lower urinary tract dysfunction. Neurourology and Urodynamics, 2018, 37, 2414-2424.	1.5	5
94	Sensitivity to the thromboxane A2 analog U46619 varies with inner diameter in human stem villous arteries. Placenta, 2016, 39, 111-115.	1.5	4
95	Liquid chromatography-mass spectrometry identification of serum biomarkers for nocturia in aged men. World Journal of Urology, 2019, 37, 2199-2205.	2.3	4
96	Cell Versus Chemokine Therapy Effects on Cell Mobilization to Chronically Dysfunctional Urinary Sphincters of Nonhuman Primates. International Neurourology Journal, 2018, 22, 260-267.	1.3	4
97	Stem and Progenitor Cells in Regenerative Pharmacology. , 2013, , 75-126.		3
98	Gene Therapy in Erectile Dysfunction: Dead or Alive?. Journal of Sexual Medicine, 2020, 17, 1587-1589.	0.6	3
99	Re: Spontaneous Release of Acetylcholine from Autonomic Nerves in the Bladder. European Urology, 2010, 57, 171-172.	1.9	2
100	Transcriptome analysis of bladder biopsy from interstitial cystitis/bladder pain syndrome patients. Genomics Data, 2014, 2, 366-368.	1.3	2
101	Are there relevant animal models to set research priorities in LUTD? ICIERS 2019. Neurourology and Urodynamics, 2020, 39, S9-S15.	1.5	2
102	URODYNAMIC CHARACTERIZATION OF MICE LACKING UROPLAKIN II OR III. FASEB Journal, 2007, 21, A1308.	0.5	2
103	Are female lower urinary tract symptoms alleviated by α -adrenoreceptor antagonists?. Nature Reviews Urology, 2008, 5, 586-587.	1.4	1
104	Animal Models of Regenerative Medicine. , 2013, , 219-234.		1
105	The potential utility of non-invasive imaging to monitor restoration of bladder structure and function following subtotal cystectomy (STC). BMC Urology, 2015, 15, 103.	1.4	1
106	Regenerative pharmacology in urology. Investigative and Clinical Urology, 2017, 58, 79.	2.0	1
107	Development of contractile properties in the fetal porcine urinary bladder. Pediatric Research, 2018, 83, 148-155.	2.4	1
108	Re: Systemic Therapy for Bladder Pain Syndrome/Interstitial Cystitis (BPS/IC): Systematic Review of Published Trials in the Last 5 Years. European Urology, 2021, 79, 431-432.	1.9	1

#	ARTICLE	IF	CITATIONS
109	Gap Junction-Mediated Therapies to Eliminate Cardiac Arrhythmias. , 0, , 237-251.		1
110	Characterization of a Murine Model of Bioequivalent Bladder Wound Healing and Repair Following Subtotal Cystectomy. BioResearch Open Access, 2017, 6, 35-45.	2.5	1
111	Future Considerations in Overactive Bladder Pharmacotherapy. , 2019, , 219-229.		1
112	Incontinence in Patients With Underactive Bladder. International Neurourology Journal, 2020, 24, 293-294.	1.3	1
113	Regenerative Pharmacology of the Bladder. , 2013, , 15-33.		1
114	Introduction to Regenerative Pharmacology: A Short Primer on the Role of Pharmacological Sciences in Regenerative Medicine. , 2013, , 3-14.		1
115	Kidney and Bladder Regeneration: Pharmacologic Methods. , 0, , 52-72.		0
116	What's hot from the ICS Annual Meeting 2006. Neurourology and Urodynamics, 2007, 26, 148-153.	1.5	0
117	The evolving physiology of the lower urinary tract: What we are learning and where we need to go. Current Bladder Dysfunction Reports, 2009, 4, 81-85.	0.5	0
118	Future therapies: Early trials and basic science. Canadian Urological Association Journal, 2013, 7, 179.	0.6	0
119	Micro- and Nanoscale Delivery of Therapeutic Agents for Regenerative Therapy. , 2013, , 127-156.		0
120	Mechanical Control of Adult Mesenchymal Stem Cells in Cardiac Applications. , 2013, , 34-51.		0
121	The Past, Present, and Future of Tissue Regeneration. , 0, , 311-328.		0
122	Incorporation of Active Factors (Pharmacological Substances) in Biomaterials for Tissue Engineering. , 0, , 167-189.		0
123	Re: Nonantimuscarinic Treatment for Overactive Bladder: A Systematic Review. European Urology, 2016, 70, 1077.	1.9	0
124	Re: Inhibition of Cholinergic Neurotransmission by β_2 3 -adrenoceptors Depends on Adenosine Release and A 1 Receptors Activation in Human and Rat Urinary Bladders. European Urology, 2017, 72, 650-651.	1.9	0
125	Inside Front Cover Image, Volume 39, Number 2, February 2020. Neurourology and Urodynamics, 2020, 39, ii.	1.5	0
126	Voiding patterns in uroplakin II knockout mice. FASEB Journal, 2007, 21, A1301.	0.5	0

#	ARTICLE	IF	CITATIONS
127	Threshold gene transfer with hSlo enhances sildenafil-induced erectile responses in 2 month streptozotocin(STZ)-diabetic rats. FASEB Journal, 2007, 21, A420.	0.5	0
128	Studies of tissue regeneration in a rat bladder model in vivo. FASEB Journal, 2009, 23, 939.1.	0.5	0
129	Maturation and growth of the bladder wall in a rodent model of organ regeneration. FASEB Journal, 2010, 24, 754.1.	0.5	0
130	Studies of age-related impairments in regenerative capacity in adult mammals using the rodent bladder. FASEB Journal, 2011, 25, 1087.13.	0.5	0
131	Bioreactor Technologies for Tissue Engineering a Replacement Heart Valve. , 0, , 157-166.		0
132	Enabling Drug Discovery Technologies for Regenerative Pharmacology. , 0, , 190-218.		0
133	Regenerative Cardiac Pharmacology: Translating Stem Cell Biology into Therapeutic Solutions. , 0, , 252-269.		0
134	Wound Healing and Cell Therapy for Muscle Repair. , 0, , 270-289.		0
135	Regenerative Pharmacology of Implanted Materials and Tissue-Engineered Constructs. , 2013, , 290-310.		0